小细胞肺癌的靶向治疗

doi:10.3760/cma.j.issn.1673,422X.2015.06.014

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (6): 452-454.doi: 10.3760/cma.j.issn.1673,422X.2015.06.014

小细胞肺癌的靶向治疗

王文娴,张沂平

310022杭州，浙江中医药大学附属浙江省肿瘤医院化疗中心

收稿日期:2014-10-31 出版日期:2015-06-08 发布日期:2015-05-31
通讯作者: 张沂平，Email: zyp@medmail.com.cn E-mail:张沂平，Email: zyp@medmail.com.cn
基金资助:
卫生部医药卫生科技发展研究中心课题（W2012FZ134）；浙江省自然科学基金（LY13H160024）

Targeted therapy for small cell lung cancer

Wang Wenxian, Zhang Yiping

Department of Chemotherapy, Zhejiang Cancer Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310022, China

Received:2014-10-31 Online:2015-06-08 Published:2015-05-31
Contact: Zhang Yiping E-mail:张沂平，Email: zyp@medmail.com.cn

摘要/Abstract

摘要： 小细胞肺癌（SCLC）靶向治疗药物包括血管生成抑制剂、酪氨酸激酶抑制剂和信号通路抑制剂等。研究表明血管生成抑制剂如贝伐珠单抗疗效并不显著；酪氨酸激酶抑制剂如舒尼替尼等可能更适合单药治疗；信号通路抑制剂如Amuvatinib、LDE225等正在进行Ⅰ、Ⅱ期临床试验。目前认为SCLC对于靶向治疗不敏感，或更具有选择性和针对性，有待于进一步研究。

关键词: 肺肿瘤, 癌,小细胞, 靶向治疗

Abstract: argeted agents for small cell lung cancer (SCLC) include inhibitors of angiogenesis, tyrosine kinase inhibitors and signal transduction pathway inhibitors. Bevacizumab, a class of antiangiogenic agent, tends to have no effects on patients. The tyrosine kinase inhibitor, for example sunitinib, may be used as a monotherapy. Signaling inhibitors including Amuvatinib and LDE225 are undergoing phaseⅠand Ⅱ trials. Primary data show that SCLC is not sensitive to targeted therapy, needing more selection, so further studies are requested.

Key words: Lung neoplasms, Carcinoma, small cell, Targeted therapy

王文娴,张沂平. 小细胞肺癌的靶向治疗[J]. 国际肿瘤学杂志, 2015, 42(6): 452-454.

Wang Wenxian, Zhang Yiping. Targeted therapy for small cell lung cancer[J]. Journal of International Oncology, 2015, 42(6): 452-454.

参考文献

［1］ Kalemkerian G, Akerley W, Bogner P, et al. Small cell lung cancer［J］. Natl Compr Canc Netw, 2013, 11(1): 78-98. ［2］ Wojcik E, Jakubowicz J, Skotnicki P, et al. IL6 and VEGF in small cell lung cancer patients［J］. Anticancer Res, 2010, 30(5): 1773-1778. ［3］ Horn L, Dahlberg S, Sandler A, et al. Phase Ⅱ study of cisplatin plus etoposide and bevacizumab for previously untreated, extensivestage smallcell lung cancer［J］. J Clin Oncol, 2009, 27(35): 6006-6011. ［4］ Ready N, Dudek A, Pang H, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensivestage smallcell lung cancer: CALGB 30306, a phase Ⅱ study［J］. J Clin Oncol, 2011, 29(33): 4436-4441. ［5］ Spigel D, Townley P, Waterhouse D, et al. Randomized phase Ⅱ study of bevacizumab in combination with chemotherapy in previously untreated extensivestage smallcell lung cancer: results from the SALUTE trial［J］. J Clin Oncol, 2011, 29(16): 2215-2222. ［6］ Pujol J, Lavole A, Quoix E, et al. Randomized phase Ⅱ/Ⅲ study of bevacizumab in combination with chemotherapy in previously untreated extensive smallcell lung cancer: IFCT0802 trial［J］. J Clin Oncol, 2014, 32(15): 478-478. ［7］ Lu S, Li L, Luo Y, et al. Randomized phase Ⅱ study of recombinant human endostatin in combination with chemotherapy in previously untreated extensivestage smallcell lung cancer (NCT00912392)［J］. J Clin Oncol, 2012, 30(15): 98-102. ［8］ Rachel E, Sanborn J, Patel G, et al. A randomized doubleblind phase Ⅱ trial of platinum plus etoposide with or without cocurrent ZD6474(Z) in patients with previously untreated extensivestage small cell lung cancer: Hoosier Oncology Group LUN06113［J］. J Clin Oncol, 2014, 32(15s): 7506. ［9］ Schneider B, Gadgeel S, Ramnath N, et al. Phase Ⅱ trial of sunitinib maintenance therapy after platinumbased chemotherapy in patients with extensivestage small cell lung cancer［J］. J Thorac Oncol, 2011, 6(6): 1117-1120. ［10］ Han J, Kim H, Lim K, et al. A phase Ⅱ study of sunitinib in patients with relapsed or refractory small cell lung cancer［J］. Lung Cancer, 2013, 79(2): 137-142. ［11］ David R, Spigel A, Spira R, et al. PhaseⅠb of anticancer stem cell antibody OMG59R5 in combination with etoposide and cisplatin in patients with untreated extensivestage small cell lung cancer［J］. J Clin Oncol, 2014, 32(15s): 7601. ［12］ Schmid K, BagoHorvath Z, Berger W, et al. Dual inhibition of egfr and mtor pathways in small cell lung cancer［J］. Br J Cancer, 2010, 103(5): 622-628. ［13］ Tarhini A, Kotsakis A, Gooding W, et al. Phase Ⅱ study of everolimus (RAD001) in previously treated small cell lung cancer［J］. Clin Cancer Res, 2010, 16(23): 5900-5907. ［14］ Besse B, Heist R, Papadmitrakopoulou V, et al. A phaseⅠb doseescalation study of everolimus combined with cisplatin and etoposide as firstline therapy in patients with extensivestage smallcell lung cancer［J］. Ann Oncol, 2014, 25(2): 505-511. ［15］ Tibes R, Fine G, Choy G, et al. A phase Ⅰ firstinhuman doseescalation study of amuvatinib, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumors［J］. Cancer Chemother Pharmacol, 2013, 71(2): 463-471. ［16］ Mita M, Gordon M, Rosen L, et al. Phase Ⅰb study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors［J］. Cancer Chemother Pharmacol, 2014, 74(1): 195-204. ［17］ Park K, Martelotto L, Peifer M, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer［J］. Nat Med, 2011, 17(11): 1504-1508. ［18］ Maria C, Lee M, Krug A, et al. Phase Ⅰ trial of the hedgehog inhibitor, LDE225, in combination with etoposide and cisplatin for initial treatment of extensive stage small cell lung cancer［J］. J Clin Oncol, 2014, 32(5s): 7602. ［19］ Langer C, Albert L, Kovacs P, et al. Randomized phase Ⅱ study of carboplatin and etoposide with or without obatoclax mesylate in extensivestage small cell lung cancer［J］. Lung Cancer, 2014, 85(3): 420-428. ［20］ Paik P, Rudin C, Pietanza M, et al. A phase Ⅱ study of obatoclax mesylate, a BCL2 antagonist, plus topotecan in relapsed small cell lung cancer［J］. Lung Cancer, 2011, 74(3): 481-485. ［21］ Baggstrom M, Qi Y, Koczywas M, et al. A phase Ⅱ study of AT101 (Gossypol) in chemotherapysensitive recurrent extensivestage small cell lung cancer［J］. J Thorac Oncol, 2011, 6(10): 1757-1760. ［22］ Schelman W, Mohammed T, Traynor A, et al. A phase Ⅰ study of AT101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensivestage small cell lung cancer［J］. Invest New Drugs, 2014, 32(2): 295-302.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[5]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[8]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[9]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[10]	王婷, 李文倩, 解友邦. 低氧与急性髓系白血病细胞氧感受通路的相关性[J]. 国际肿瘤学杂志, 2023, 50(8): 503-507.
[11]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[12]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[15]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.

小细胞肺癌的靶向治疗

Targeted therapy for small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价